Adherex Technologies Q1 Earnings Call Highlights
Key takeaways
- Adherex Technologies Q1 Earnings Call Highlights Market Beat Thu, May 14, 2026 at 10:06 PM GMT+7 7 min read FENC Key Points Interested in Adherex Technologies Inc.?
- Fennec Pharmaceuticals reported strong Q1 2026 results, with net product sales rising about 73% year over year to $15.1 million and positive operating cash flow.
- The company’s expanded sales force under Project Ignite is starting to pay off, with the target prescriber base growing from roughly 1,300 to more than 5,000.
Adherex Technologies Q1 Earnings Call Highlights Market Beat Thu, May 14, 2026 at 10:06 PM GMT+7 7 min read FENC Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better.
Fennec Pharmaceuticals reported strong Q1 2026 results, with net product sales rising about 73% year over year to $15.1 million and positive operating cash flow. Management said it was the sixth straight quarter of sales growth.
The company’s expanded sales force under Project Ignite is starting to pay off, with the target prescriber base growing from roughly 1,300 to more than 5,000. Executives said the broader reach is driving demand from both new and existing prescribers, while the Fennec HEARS support program boosted completed infusions and hit an 80% conversion benchmark for the first time.